Promises and challenges of fluorescence cystoscopy

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Introduction: Fluorescence based photodynamic diagnostic (PDD) techniques have been developed to improve detection and treatment of non-muscle invasive bladder cancer. The goal of this article is to evaluate the promises and challenges of blue light cystoscopy. Methods: The literature was reviewed regarding articles pertaining to fluorescent cystoscopy and blue light cystoscopy (BLC). Results: Blue light cystoscopy improves detection of bladder cancer tumors especially CIS. Randomized trials have demonstrated a reduction of recurrences. BLC has been demonstrated to be safe and effective in treatment of NMIBC of varying risk. The main obstacle to BLC will be adoption by urologists. Purchase cost of capital equipment may impact usage especially if adopted for outpatient clinics. Conclusions: BLC has been demonstrated to be safe and effective in treatment of NMIBC of varying risk. The reduction of recurrences and yet unproven but potential reduction in progression should be viewed favorably by urologists and patients. The main obstacle to BLC will be adoption by urologists who can put pressure on hospitals to acquire the capital equipment and who will seek the training to become proficient in using the technology. Patient demand for the technology may also help increase availability. Finally, the companies involved with BLC need to support trials that will demonstrate reduction in progression and that will answer the practical issues regarding usage in proximity to BCG and repeated usage.

Original languageEnglish (US)
Pages (from-to)261-264
Number of pages4
JournalUrologic Oncology: Seminars and Original Investigations
Volume33
Issue number6
DOIs
StatePublished - Jun 1 2015

Fingerprint

Cystoscopy
Fluorescence
Light
Urinary Bladder Neoplasms
Economics
Technology
Recurrence
Mycobacterium bovis
Ambulatory Care Facilities
Therapeutics
Pressure
Costs and Cost Analysis

Keywords

  • Blue light cystoscopy
  • Fluorescence-based photodynamic diagnostic
  • Nonmuscle invasive bladder cancer

ASJC Scopus subject areas

  • Oncology
  • Urology

Cite this

Promises and challenges of fluorescence cystoscopy. / Lotan, Yair.

In: Urologic Oncology: Seminars and Original Investigations, Vol. 33, No. 6, 01.06.2015, p. 261-264.

Research output: Contribution to journalArticle

@article{fab71cd3b2584fbcbb9e800a50587346,
title = "Promises and challenges of fluorescence cystoscopy",
abstract = "Introduction: Fluorescence based photodynamic diagnostic (PDD) techniques have been developed to improve detection and treatment of non-muscle invasive bladder cancer. The goal of this article is to evaluate the promises and challenges of blue light cystoscopy. Methods: The literature was reviewed regarding articles pertaining to fluorescent cystoscopy and blue light cystoscopy (BLC). Results: Blue light cystoscopy improves detection of bladder cancer tumors especially CIS. Randomized trials have demonstrated a reduction of recurrences. BLC has been demonstrated to be safe and effective in treatment of NMIBC of varying risk. The main obstacle to BLC will be adoption by urologists. Purchase cost of capital equipment may impact usage especially if adopted for outpatient clinics. Conclusions: BLC has been demonstrated to be safe and effective in treatment of NMIBC of varying risk. The reduction of recurrences and yet unproven but potential reduction in progression should be viewed favorably by urologists and patients. The main obstacle to BLC will be adoption by urologists who can put pressure on hospitals to acquire the capital equipment and who will seek the training to become proficient in using the technology. Patient demand for the technology may also help increase availability. Finally, the companies involved with BLC need to support trials that will demonstrate reduction in progression and that will answer the practical issues regarding usage in proximity to BCG and repeated usage.",
keywords = "Blue light cystoscopy, Fluorescence-based photodynamic diagnostic, Nonmuscle invasive bladder cancer",
author = "Yair Lotan",
year = "2015",
month = "6",
day = "1",
doi = "10.1016/j.urolonc.2015.03.019",
language = "English (US)",
volume = "33",
pages = "261--264",
journal = "Urologic Oncology: Seminars and Original Investigations",
issn = "1078-1439",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Promises and challenges of fluorescence cystoscopy

AU - Lotan, Yair

PY - 2015/6/1

Y1 - 2015/6/1

N2 - Introduction: Fluorescence based photodynamic diagnostic (PDD) techniques have been developed to improve detection and treatment of non-muscle invasive bladder cancer. The goal of this article is to evaluate the promises and challenges of blue light cystoscopy. Methods: The literature was reviewed regarding articles pertaining to fluorescent cystoscopy and blue light cystoscopy (BLC). Results: Blue light cystoscopy improves detection of bladder cancer tumors especially CIS. Randomized trials have demonstrated a reduction of recurrences. BLC has been demonstrated to be safe and effective in treatment of NMIBC of varying risk. The main obstacle to BLC will be adoption by urologists. Purchase cost of capital equipment may impact usage especially if adopted for outpatient clinics. Conclusions: BLC has been demonstrated to be safe and effective in treatment of NMIBC of varying risk. The reduction of recurrences and yet unproven but potential reduction in progression should be viewed favorably by urologists and patients. The main obstacle to BLC will be adoption by urologists who can put pressure on hospitals to acquire the capital equipment and who will seek the training to become proficient in using the technology. Patient demand for the technology may also help increase availability. Finally, the companies involved with BLC need to support trials that will demonstrate reduction in progression and that will answer the practical issues regarding usage in proximity to BCG and repeated usage.

AB - Introduction: Fluorescence based photodynamic diagnostic (PDD) techniques have been developed to improve detection and treatment of non-muscle invasive bladder cancer. The goal of this article is to evaluate the promises and challenges of blue light cystoscopy. Methods: The literature was reviewed regarding articles pertaining to fluorescent cystoscopy and blue light cystoscopy (BLC). Results: Blue light cystoscopy improves detection of bladder cancer tumors especially CIS. Randomized trials have demonstrated a reduction of recurrences. BLC has been demonstrated to be safe and effective in treatment of NMIBC of varying risk. The main obstacle to BLC will be adoption by urologists. Purchase cost of capital equipment may impact usage especially if adopted for outpatient clinics. Conclusions: BLC has been demonstrated to be safe and effective in treatment of NMIBC of varying risk. The reduction of recurrences and yet unproven but potential reduction in progression should be viewed favorably by urologists and patients. The main obstacle to BLC will be adoption by urologists who can put pressure on hospitals to acquire the capital equipment and who will seek the training to become proficient in using the technology. Patient demand for the technology may also help increase availability. Finally, the companies involved with BLC need to support trials that will demonstrate reduction in progression and that will answer the practical issues regarding usage in proximity to BCG and repeated usage.

KW - Blue light cystoscopy

KW - Fluorescence-based photodynamic diagnostic

KW - Nonmuscle invasive bladder cancer

UR - http://www.scopus.com/inward/record.url?scp=84929961325&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929961325&partnerID=8YFLogxK

U2 - 10.1016/j.urolonc.2015.03.019

DO - 10.1016/j.urolonc.2015.03.019

M3 - Article

C2 - 25937623

AN - SCOPUS:84929961325

VL - 33

SP - 261

EP - 264

JO - Urologic Oncology: Seminars and Original Investigations

JF - Urologic Oncology: Seminars and Original Investigations

SN - 1078-1439

IS - 6

ER -